

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**22-334**

**MICROBIOLOGY REVIEW(S)**

# Product Quality Microbiology Review

20 MARCH 2009

**NDA:** NDA 22-334/N-000

**Drug Product Name**

**Proprietary:**

Afinitor®

**Non-proprietary:**

everolimus

**Review Number:** 1

**Dates of Submission(s) Covered by this Review**

Letter	Stamp	Review Request	Assigned to Reviewer
27 JUNE 2008	30 JUNE 2008	24 JULY 2008	29 JULY 2008
09 SEP 2008 (BC)	09 SEP 2008	n/a	n/a
20 JAN 2009 (BC)	21 JAN 2009	n/a	n/a

**Submission History (for amendments only):** N/A

**Applicant/Sponsor**

**Name:**

Novartis Pharmaceuticals Corporation

**Address:**

One Health Plaza

East Hanover, New Jersey 07936-1080

**Representative:**

Sibylle R. Jennings, Ph.D.

Associate Dir. Drug Regulatory Affairs

**Telephone:**

(862) 778-1196

**Name of Reviewer:**

Robert J. Mello, Ph.D.

**Conclusion:**

The application is recommended for approval from microbiology product quality standpoint.

---

## Product Quality Microbiology Data Sheet

- A.
1. **TYPE OF SUBMISSION:** New NDA
  2. **SUBMISSION PROVIDES FOR:** Marketing Approval
  3. **MANUFACTURING SITE:** Novartis Pharma Stein AG  
Schaffhauserstrasse  
CH-4332 Stein  
Switzerland
  4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:** Tablet; Oral; 5mg and 10mg
  5. **METHOD(S) OF STERILIZATION:** N/A
  6. **PHARMACOLOGICAL CATEGORY:** Anti-neoplastic drug
- B. **SUPPORTING/RELATED DOCUMENTS:** None
- C. **REMARKS:**
- The ONDQA PAL Initial Quality Assessment was submitted to DFS on 04 AUG 2008. No microbiology issues were identified in that review.
  - The submission, in electronic eCTD format, was available via the Global Submit document system.
  - This 505 (b)(1) application was granted Priority Review designation in DSS. There were numerous amendments to the submission (42 items within the Global submit system).
  - On 30 OCT 2008 the original 30 DEC 2008 goal date was extended to the new date of March 2009 as a result of the receipt of a major amendment.
  - The Afinitor® tablet (everolimus) was formerly known as "RAD001" during the development program. As a result, much of the submitted documentation refers to RAD001.

Filename: N022334N000R1.doc

---

**Executive Summary**

**I. Recommendations**

- A. Recommendation on Approvability – Recommend Approval
- B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable –

**II. Summary of Microbiology Assessments**

- A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – The oral tablets are prepared in \_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_

b(4)

- B. Brief Description of Microbiology Deficiencies - None
- C. Assessment of Risk Due to Microbiology Deficiencies – N/A

**III. Administrative**

- A. Reviewer's Signature \_\_\_\_\_  
Robert Mello, Ph.D.

- B. Endorsement Block \_\_\_\_\_  
Bryan S. Riley, Ph.D.

- C. CC Block  
NDA 22-334

4 Page(s) Withheld

Trade Secret / Confidential (b4)

Draft Labeling (b4)

Draft Labeling (b5)

Deliberative Process (b5)

Withheld Track Number: Microbiology- 4

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.